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Abstract
Background
Pre-transfusion tests vary in sensitivity and specificity 
and should be evaluated before their implementation 
into routine use. The aim of this study was to evaluate 
the diagnostic accuracy of the Grifols DG Gel column ag-
glutination system and to compare the data with two 
other column agglutination systems used in our labo-
ratory: Ortho BioVue and Bio-Rad. Special attention 
was focused on using more vials of reagent red blood 
cells by Grifols DG Gel system when compared to other 
systems in order to investigate whether it increases the 
sensitivity for clinically significant antibodies. 
Methods
All samples were tested in parallel with Grifols DG Gel, Or-
tho BioVue and Bio-Rad cards according to manufactures’ 
instructions. Samples were processed through manual 
instrumentation. Tests were performed by trained and 
experienced staff. A total of 419 tests were performed on 
302 samples.
Results
Concordant results between Grifols DG Gel system and 
the other two systems were obtained in 93.8% of the 
tests. For antibody screening by Grifols DG Gel system, 
sensitivity was 97.53%, specificity was 100%, predictive 
positive value was 100% and predictive negative value 
was 97.73%. For antibody identification, the accuracy 
was 96.03% for Grifols DG Gel system, 97.22% for Ortho 
BioVue and 94.44% for Bio-Rad. 
Conclusions
The Grifols DG gel system shows high diagnostic accu-
racy and is safe for pre-transfusion compatibility pro-
cedures in blood transfusion laboratories. Using more 
vials of reagent red blood cells by Grifols DG Gel system 
when compared to other systems increases the sensi-
tivity for some antibody specificities, particularly anti-
Jka. This could have major impact on the prevention of 
delayed transfusion reactions. 
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antigens9, which is particularly important for the pre-
vention of delayed transfusion reactions10.
The aim of this study was to evaluate the performance 
of the Grifols DG Gel system for antibody screening and 
antibody identification through manual instrumenta-
tion [Grifols DG Therm and Grifols DG Spin (Diagnostics 
Grifols, S.A. Barcelona, Spain)], with a special focus on 
using more vials of reagent RBCs when compared to 
those used with other systems in our laboratory in or-
der to investigate whether it increases the sensitivity for 
clinically significant antibodies. 
2.  Methods
2.1. Study design
Study was conducted at the Department of Transfu-
sion Medicine of the Clinical Department of Transfusion 
Medicine and Transplantation Biology, University Clini-
cal Hospital Zagreb from January to July 2016. A total of 
419 tests were performed on 302 samples: 167 antibody 
screenings on 167 samples and 252 antibody identifica-
tion panels on 135 samples.
For antibody screening 86 patient samples of whole 
blood collected in ethylenediaminetetraacetic acid 
within 24 hours from sampling and 81 plasma samples 
containing antibodies of known specificity were used. 
Of the 81 samples with antibodies of known specificity, 
there were 57 samples with one antibody specificity, 20 
samples with two antibody specificities and 4 samples 
with three antibody specificities; in total 109 antibody 
specificities. 
For antibody identification 135 plasma samples con-
taining antibodies of known specificity were used. Of 
these, there were 103 samples with one antibody speci-
ficity, 29 samples with two antibody specificities and 3 
samples with three antibody specificities; in total 170 
antibody specificities. 
Plasma samples containing antibodies of known speci-
ficity had been stored at -30 ºC and were thawed imme-
diately before testing. 
2.2. Materials
For the Grifols DG Gel card reagent RBCs 0.8% Serascan 
Diana 4 (four cells) were used for antibody screening, 
1.  Introduction
The demands of blood transfusion laboratories are 
growing, especially in the aspect of patient safety, per-
formance and cost-effectiveness. For the purpose of 
rationalisation of pre-transfusion testing protocols, a 
method in which antibody screening determines the 
presence of only clinically significant antibodies is pre-
ferred in blood transfusion laboratories1. Published 
comparisons of antibody detection methods (conven-
tional tube, solid-phase, column agglutination) has 
shown variations in methods’ sensitivity and specifici-
ty2-5. Clinically insignificant antibodies may be detected 
at a higher rate, particularly if methods are more sensi-
tive. Understanding the strengths and limitations of val-
idated methods used can optimize antibody detection6. 
Column agglutination technology (CAT) that uses a gel 
or a glass beads matrix in microtubes for the agglutina-
tion detection has been successfully applied for over 25 
years7. The well-known advantages of CAT over the tube 
technology are: the washing step in the anti-globulin 
phase is omitted resulting in the faster performance, 
the reaction in the column is stable facilitating interpre-
tation of the weak reactions and enabling reading reac-
tions repeatedly, and there is also the possibility of au-
tomation which decreases human errors and provides 
the traceability of the results8. 
Grifols DG Gel (Diagnostic Grifols S.A., Barcelona, Spain) 
is a new column agglutination system on the Croatian 
market for pre-transfusion testing. The Grifols DG Gel 
system can be used in manual techniques or through 
full automation instrumentation with a small capac-
ity Wadiana analyser, a medium capacity Erytra Eflexis 
analyser, which is a new analyser on the market, or with 
a high throughput high capacity Erytra analyser (Diag-
nostics Grifols, S.A. Barcelona, Spain).
Before implementing the new system into routine use, 
an evaluation to confirm sensitivity and specificity of 
the system should be done. Major advantage of the Gri-
fols DG Gel system is an 8-column gel card, which allows 
more flexibility in choosing reagent RBCs for antibody 
screening and antibody identification with more ex-
amples of phenotypes expressing and lacking the cor-
responding antigen when compared to 6-column cards. 
Using more vials of reagent red blood cells (RBCs) for 
antibody screening and antibody identification en-
hances double-dose expression of clinically relevant 
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2.4. Interpretation of results
A positive reaction is agglutination seen if RBCs are re-
tained in the column. A negative reaction is absence of 
agglutination seen if packed RBCs are fallen at the bot-
tom of the column. In antibody screening the reactivity 
of the serum as whole was evaluated in cases of mul-
tiple antibodies, regardless of whether one or all anti-
bodies present were observed to be positive. 
Antibody identification was performed according to 
the British Committee for Standards in Haematology 
(BSCH) (10). The presence of additional antibodies was 
excluded.
The result was considered to be false positive when a 
positive result did not correlate with antibody speci-
ficity. The result was considered to be a false negative 
when the result with samples containing antibodies of 
known specificity was negative. All discrepancies were 
resolved.
2.5. Statistical analysis
The results were processed by statistical software SPSS 
25. Descriptive statistics was used in the statistical anal-
ysis. Sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV) and the accuracy 
of CAT systems were calculated according to standard 
formulae including the 95% confidence intervals (CI)11.
3.  Results
Concordant results between Grifols DG Gel and other 
two systems were observed for 393 of the 419 (93.8%) 
tests. Antibody specificities of the samples for antibody 
screening and identification are shown in Table 1.
3.1. Antibody screening
Of the 167 samples with antibody screening performed, 
discordant results were observed in 3 (1.8%) samples 
(Table 2). All discordant results were false negative: 2 in 
Grifols DG Gel (anti-M and -K) and 1 in Bio-Rad (anti-E). 
The results of the antibody screening test with estimat-
ed sensitivity, specificity, PPV, NPV and the accuracy of 
the compared systems are shown in Table 3. 
while 0.8% Identisera Diana and Identisera Diana P 
(1-11 cells) together with Identisera Diana Extend and 
Identisera Diana Extend P (12-15 cells) were used for an-
tibody identification. For the indirect anti-globulin (IAT) 
test and the enzyme test, DG Gel Coombs and DG Gel 
Neutral cards were used, respectively. 
The Ortho BioVue card used reagent RBCs 0.8% Surgis-
creen (three cells) for antibody screening and 0.8% Or-
tho Resolve Panel C (1-11 treated and untreated cells) 
for antibody identification. For the IAT test and the en-
zyme test anti-human globulin anti-IgG; -C3d polyspe-
cific and Neutral cards were used, respectively. 
For the Bio-Rad card reagent RBCs ID-DiaCell I-II (two 
cells) were used for antibody screening, while ID-DiaP-
anel and ID-DiaPanel-P (1-11 cells) were used for an-
tibody identification. For the IAT and the enzyme test 
ID-LISS/Coombs and NaCl, Enzyme test and Cold Agglu-
tinins cards were used, respectively. 
Both IAT and the enzyme test were performed for anti-
body identification. 
2.3. Methods
All samples were tested in parallel with Grifols DG Gel, 
Ortho BioVue (Ortho-Clinical Diagnostics, Inc., Raritan, 
NJ, USA) and Bio-Rad cards (Bio-Rad Laboratories, Inc., 
CA, USA) according to manufactures’ instructions. Sam-
ples were processed through manual instrumentation 
(Grifols DG Therm and Grifols DG Spin in case of the DG 
Gel System; Ortho BioVue System Heat Block and Ortho 
BioVue System for Ortho BioVue cards; Bio-Rad ID-cards 
were processed through manual instrumentation in the 
Bio-Rad Gel Test ID-Micro Typing system). Tests were 
performed by trained and experienced staff. 
For the Grifols DG Gel system, the technique consisted 
of pipetting 50 μL of reagent RBCs and 25 μL of plasma 
in the microtube, 15 minutes of incubation and 9 min-
utes of centrifugation. 
For the Ortho BioVue system, the technique consisted 
of pipetting 50 μL of reagent RBCs and 40 μL of plasma 
in the microtube, 15 minutes of incubation and 5 min-
utes of centrifugation. 
For the Bio-Rad system, the technique consisted of pi-
petting 50 μL of reagent RBCs and 25 μL of plasma in the 
microtube, 15 minutes of incubation and 10 minutes of 
centrifugation. 
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Table 1. Antibody specificities of the samples for antibody screening and identification
Antibody 
specificity















anti-C 0 13 13 (11.9) 2 14 16 (9.4)
anti-c 4 3 7 (6.4) 2 6 8 (4.7)
anti-Cw 0 1 1 (0.9) 0 2 2 (1.2)
anti-D 16 12 28 (25.7) 28 14 42 (24.7)
anti-E 6 11 17 (15.6) 19 10 29 (17.1)
anti-Fya 1 1 2 (1.8) 3 1 4 (2.4)
anti-Fyb 1 0 1 (0.9) 1 0 1 (0.6)
anti-G 0 1 1 (0.9) 0 1 1 (0.6)
anti-Jka 0 1 1 (0.9) 5 1 6 (3.5)
anti-K 13 5 18 (16.5) 20 10 30 (17.6)
anti-k 1 0 1 (0.9) - - -
anti-Kpa 0 1 1 (0.9) 1 2 3 (1.7)
anti-Lea 4 2 6 (5.5) 5 3 8 (4.7)
anti-Lua 0 1 1 (0.9) 4 0 4 (2.4)
anti-M 10 0 10 (9.2) 12 2 14 (8.2)
anti-P1 - - - 0 1 1 (0,6)
anti-S 1 0 1 (0.9) 1 0 1 (0.6)
Σ 57 52 109 (100) 103 67 170 (100)
Table 2. Samples with discordant results in the antibody screening test
Antibody specificity DG Gel Ortho BioVue Bio-Rad
anti-E Positive Positive Negative
anti-K Negative Positive Positive
anti-M Negative Positive Positive
 Table 3. Diagnostic accuracy of antibody screening test for compared systems
Grifols DG Gel Ortho BioVue Bio-Rad
True positive 79 81 80
False positive 0 0 0
True negative 86 86 86
False negative 2 0 1
Sensitivity (95% CI) 97.53 (91.36-99.70) 100 (99.55-100) 98.77 (93.31-99.97)
Specificity (95% CI) 100 (95,80-100) 100 (95.80-100) 100 (95.80-100)
PPV (95% CI) 100 100 100
PNV (95% CI) 97.73 (91.63-99.41) 100 98.85 (92.46-99.83)
Accuracy (95% CI) 98.80 (95.74-99.85) 100 (97.82-100) 99.40 (96.71-99.98)
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no samples with nonspecific results and no sample was 
identified as a prophylactic anti-D antibody. 
Of the 23 discrepancies, Grifols DG Gel system detected 
the antibody on 13 occasions (242 identified out of 252; 
accuracy of 96.03%), Ortho BioVue on 16 occasions (245 
identified out of 252; accuracy of 97.22%) and Bio-Rad 
on 9 occasions (238 identified out of 252; accuracy of 
94.44%). 
3.2.  Antibody identification
A total of 252 tests for antibody identification were 
performed on 135 samples. Discordant results were 
observed in 23 (9.1%) tests, including IAT and the en-
zyme test (the antibody was detected with one or two 
systems). Table 4. shows the list of identified antibod-
ies and antibodies with discrepancies between Grifols 
DG Gel, Ortho BioVue and Bio-Rad systems. There were 
































anti-c+E 5 1 1 (-c) 1 (-c)
anti-c+Fya 1
anti-Cw+K 2 1 1 (-Cw) 1 (-Cw)
anti-D 28 1 1 1
anti-D+K 2
anti-E 19 2 1 2 1
anti-E+K 4 2 2 (-E) 2 (-E)
anti-Fya 3
anti-Fyb 1
anti-Jka 5 1 1
anti-K 20 1 1 1 1 1 1
anti-K+Kpa 2
anti-Kpa 1 1 1
anti-Lea 5 5 2 5 1
anti-Lea+M 1 1 1 (Lea)
anti-Lua 4 2 1 1 1 1
anti-M 12 2 1 2 1
anti-M+P1 1
Anti-S 1
Total 135 13 6 11 5 10 7 5 4
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identification tests on Erytra. Out of all discordant cases of 
antibodies in the IAT test, there were 2 examples of anti-M, 
which is a clinically significant antibody only if detectable 
at 37 ºC, 2 examples of anti-Lua and 5 examples of anti-Lea, 
which are clinically benign antibodies, while others were 
clinically significant antibodies (1 anti-D, 1 anti-K and 2 
anti-E). Of discordant cases of antibodies in the enzyme 
test, there were 7 cases of clinically significant antibodies. 
Considering that 4 of these antibodies (1 anti-C, 1 anti-c, 
2 anti-E) were detected only with enzyme-treated cells, 
their clinical significance remains controversial 15. It is 
generally accepted, that it is not possible to detect all po-
tentially clinically significant antibodies, nor to avoid all 
clinically insignificant antibodies6. Three or more positive 
results were missed by each system for different antibody 
specificities in antibody identification tests: Grifols DG Gel 
(1 anti-c, 1 anti-D, 1 anti-E, 1 anti-K, 3 anti-M and 4 anti-
Lea), Ortho BioVue (1 anti-S and 2 anti-Jka) and Bio-Rad (1 
anti-c, 1 anti-K, 1 anti-Lea, 1 anti-P1, 2 anti-Jk
a and 3 anti-
M). This benefits the Grifols DG Gel system for anti-Jka and 
-S, Ortho BioVue for anti-D, -E, -K, -Lea, -M and -P1 and Bio-
Rad for anti-D and -S antibody specificities. However, one 
must be aware of the small sample size, particularly for 
some antibody specificities in this study. 
Using more vials of reagent RBCs for antibody screening 
and antibody identification test by Grifols DG Gel sys-
tem compared to those used by other two systems re-
sulted in enhanced double-dose expression of clinically 
relevant antigens (C, c, E, e, Jka, Jkb, Fya, Fyb, M, N and S) 
and in higher sensitivity of Grifols DG Gel, particularly 
for anti-Jka antibody specificities. However, small sam-
ple size is the limitation of this study and for definite 
conclusions a bigger sample size is needed. Differences 
in the expression of rare antigens on the screening cells 
(Lua on BioRad, Cw and Kpa on Grifols DG Gel and Ortho 
BioVue) did not influence antibody detection results, as 
antibodies to rare antigens were no single antibodies. 
Being rarely of clinical significance, Lua(+), Kpa(+) and 
Cw(+) antigens are not essential on screening cells10. 
In this study, procedures were set up to follow manu-
factures’ instructions, therefore when analysing results 
different RBC suspension media (LISS), incubation time 
and centrifugation setting for each system should be 
taken into consideration. The conductivity of different 
low-ionic-strength solutions (LISS) calculated by Cid et 
al.12, shown greater value for diluents provided by Bio-
Rad (5.89 mS cm-1) and Grifols (5.09 mS cm-1), than by 
Ortho (3.03 mS cm-1). Grey et al.16 reported that higher 
conductivity of ID-CellStab (Bio-Rad) could be the origin 
of false negative results. 
There were 13 discrepancies between Grifols DG Gel, 
Ortho BioVue and Bio-Rad systems in the IAT test. These 
included 6 antibodies identified using the Grifols DG Gel 
system (single examples of anti-E, -K, -Lua, and -M and 
2 examples of anti- Lea), 11 antibodies identified using 
Ortho BioVue (single examples of anti-D and -K, 2 exam-
ples of anti-E and -M and 5 examples of anti-Lea) and 5 
antibodies identified using Bio-Rad (single examples of 
anti-D, -E, -Lea, -Lua, and -M). 
In the enzyme test, 10 discrepancies were identified; 
7 antibodies were identified using the DG Gel system 
(single examples of anti-C, -c, -Cw, -Jka and -Lua and 2 
examples of anti-E), 5 antibodies were identified using 
Ortho BioVue (single examples of anti-c, -Cw, -K and 2 ex-
amples of anti-E) and 4 antibodies were identified using 
Bio-Rad (single examples of anti-C, -K, -Kpa and -Lea). 
4.  Discussion
Overall, concordant results between Grifols DG Gel and 
the other two systems were observed for 393 tests: 164 
of 167 (98.2%) screening tests and 229 of 252 (90.9%) 
antibody identification tests.
For antibody screening, only 1.8% cases were discordant 
(anti-E, -K and -M) and they were all detected by Ortho 
BioVue; two cases were detected by Bio-Rad (anti-K and 
-M) and one case (anti-E) was detected by Grifols DG Gel. 
Sensitivity and specificity for Grifols DG Gel were 97.53% 
and 100%, respectively. In comparison to the other two 
systems, Grifols DG Gel presented a lower sensitivity, 
while specificity was equal for all systems. In a study by 
Cid et al.12, 100% of sensitivity and specificity were ob-
served for Grifols DG Gel, which presented a higher sensi-
tivity when compared to the Bio-Rad system and a higher 
specificity when compared to Ortho BioVue. In another 
study by Taylor et al.13, sensitivity and specificity for Gri-
fols DG Gel were 90.63% and 99.94%, respectively. 
Regarding antibody identification, Ortho BioVue had a 
higher diagnostic accuracy (97.22%) than both Grifols DG 
Gel and Bio-Rad (96.03% and 94.44%, respectively). The 
rates observed in this study for both Grifols DG Gel and 
Bio-Rad were a little lower than those observed by Tay-
lor et al.13 (96.95% and 95.29%, respectively). Also, Chang 
et al.14 showed a higher accuracy (100%) for the antibody 
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5.  Conclusions
In conclusion, the Grifols DG Gels system is safe for 
routine pre-transfusion compatibility procedures (anti-
body screening and identification) in blood transfusion. 
Using more vials of reagent red blood cells by Grifols 
DG Gel when compared to other methods used in the 
laboratory increases the sensitivity for some antibody 
specificities, particularly anti-Jka. This could have ma-
jor impact on the prevention of delayed transfusion re-
actions. 
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Zaključci
Sustav Grifols DG gel pokazuje visoku dijagnostičku 
točnost i siguran je za predtransfuzijsko ispitivanje. 
Upotrebom više bočica test eritrocita sustavom Grifols 
DG Gel u usporedbi s drugim sustavima povećava se 
osjetljivost za neke specifičnosti protutijela, posebno 
anti-Jka. To bi moglo imati velik utjecaj na prevenciju 
odgođenih transfuzijskih reakcija.
Ključne riječi: evaluacija programa, krvne grupe i crossmatch-
ing, testovi hemaglutinacije, eritrociti, aloantitijela
Sažetak
Uvod
Testovi za predtransfuzijsko ispitivanje razlikuju se pre-
ma osjetljivosti i specifičnosti i trebalo bi ih validirati 
prije primjene za rutinski rad. Cilj ove studije bio je pro-
cijeniti dijagnostičku točnost sustava aglutinacije u mi-
krostupcu Grifols DG Gel i usporediti podatke s još dva 
sustava aglutinacije u mikrostupcu koji se primjenjuju 
u našem laboratoriju: Ortho BioVue i Bio-Rad. Posebna 
pozornost posvećena je upotrebi više bočica test eri-
trocita kod sustava Grifols DG Gel u usporedbi s drugim 
sustavima kako bi se istražilo povećava li se osjetljivost 
za klinički značajna protutijela.
Materijal i metode
Svi uzorci testirani su paralelno karticama Grifols DG 
Gel, Ortho BioVue i Bio-Rad prema uputama proizvo-
đača. Uzorci su obrađeni ručno. Ispitivanja su obavili 
obučeni i iskusni djelatnici. Ukupno je provedeno 419 
ispitivanja na 302 uzorka.
Rezultati
Podudarni rezultati između sustava Grifols DG Gel i osta-
la dva sustava dobiveni su u 93,8 % ispitivanja. Za pre-
traživanje antieritrocitnih protutijela sustavom Grifols 
DG Gel osjetljivost je bila 97,53 %, specifičnost 100 %, 
prediktivna pozitivna vrijednost 100  % i prediktivna 
negativna vrijednost 97,73 %. Za identifikaciju specifič-
nosti protutijela točnost za sustav Grifols DG Gel bila je 
96,03 %, 97,22 % za Ortho BioVue i 94,44 % za Bio-Rad.
VALIDACIJA TESTOVA PRIJETRANSFUZIJSKOG ISPITIVANJA PRETRAŽIVANJA 
I IDENTIFIKACIJE ANTIERITROCITNIH PROTUTIJELA PRIMJENOM DG GEL 
KARTICA
